Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 4,226 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable Placebo Clear all

Conditions: Type 1 Diabetes
Interventions: Denosumab, Placebo; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Birmingham, Alabama • Duarte, California • Indianapolis, Indiana

Conditions: Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia, Hernia Incisional
Interventions: OnabotulinumtoxinA Injection, Saline (placebo) Injection, OnabotulinumtoxinA, 0.9 % Normal Saline, Open Ventral Hernia Repair; Procedure · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Facetogenic Back Pain, Back Pain
Interventions: Allogeneic Human Mesenchymal Stem Cells (hMSCs), Placebo; Biological · Drug
Lead sponsor: Joshua M Hare; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lipoprotein Disorder
Interventions: DII235, Saline; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 37
States / cities: Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 33 more

Conditions: Depressive Disorder, Major
Interventions: Rapastinel, Placebo; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 17
States / cities: Birmingham, Alabama • Garden Grove, California • Glendale, California + 14 more

Conditions: Healthy Volunteers
Interventions: LY3079514, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Glendale, California

Conditions: Atopic Dermatitis
Interventions: Afimkibart, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Fountain Valley, California • Los Angeles, California • Tampa, Florida + 14 more

Conditions: Colitis, Ulcerative
Interventions: Guselkumab Dose 1, Guselkumab Dose 2, Golimumab Dose 1, Golimumab Dose 2, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 14
States / cities: San Diego, California • Colorado Springs, Colorado • Tampa, Florida + 11 more

Conditions: Eosinophilic Esophagitis
Interventions: RPC4046, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 27
States / cities: Scottsdale, Arizona • Tucson, Arizona • Oceanside, California + 24 more

Conditions: Multiple Sclerosis
Interventions: Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more

Conditions: Incisional Pain
Interventions: TAP Catheter and Infusion of Study Solution; Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: San Diego, California

Conditions: Mild Cognitive Impairment, Alzheimer Disease
Interventions: Allopregnanolone injection (intravenous solution), Placebo injection (intravenous solution); Drug
Lead sponsor: University of Southern California; Other
Eligibility: 55 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Peripheral Arterial Disease, Stenosis, Intermittent Claudication
Interventions: FGF-1, Placebo; Drug
Lead sponsor: Venturis Therapeutics, Inc.; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Polymyalgia Rheumatica
Interventions: Sarilumab SAR153191 (REGN88), Sarilumab-matching placebo, Prednisone, Prednisone-matching placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 50 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 10
States / cities: Upland, California • Denver, Colorado • Stamford, Connecticut + 7 more

Conditions: Osteoarthritis, Knee
Interventions: Ropivacaine, Ketorolac, Clonidine, Epinephrine, 0.9% sodium chloride; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Active Psoriatic Arthritis
Interventions: BMS-986165 Placebo, BMS-986165 Dose A, BMS-986165 Dose B, Ustekinumab, Ustekinumab Placebo; Other · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 31
States / cities: Huntsville, Alabama • Covina, California • La Jolla, California + 27 more

Conditions: Hypereosinophilic Syndrome
Interventions: Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more

Conditions: Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Interventions: Diranersen, Diranersen-matching placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 36
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 30 more

Conditions: Hidradenitis Suppurativa
Interventions: Placebo, Izokibep; Drug
Lead sponsor: ACELYRIN Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 50
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 44 more

Conditions: Type 1 Diabetes
Interventions: liraglutide, placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 75 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 2
States / cities: Buffalo, New York

Conditions: Lumbosacral Radicular Pain, Sciatic Radiculopathy, Sciatic Leg Pain, Sciatica, Lumbosacral Radicular Syndrome, Lumbosacral Radiculopathy
Interventions: C-1101, Placebo: Sterile Saline; Drug · Other
Lead sponsor: Consano Bio; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Fernandina Beach, Florida • Winston-Salem, North Carolina • Richmond, Virginia

Conditions: Hepatitis B, Chronic
Interventions: JNJ-73763989, Placebo for JNJ-73763989, JNJ-56136379, Placebo for JNJ-56136379, Nucleos(t)ide Analog (NA); Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 8
States / cities: Bakersfield, California • Los Angeles, California • San Clemente, California + 5 more

Conditions: Cystic Fibrosis
Interventions: novolog insulin, levemir insulin, placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 10 Years to 25 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota

Conditions: Pulmonary Arterial Hypertension
Interventions: PF-07868489, Placebo for PF-07868489; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 16
States / cities: Anaheim, California • Costa Mesa, California • Orange, California + 5 more

Search by objective public record fields.

Denosumab for Type 1 Diabetes

Preoperative BOTOX® Injection for Large Ventral Hernia Repair

Allogeneic Human Mesenchymal Stem Cell Injection in PAtieNts With FaceTogenic Back Pain

A Study of DII235 in Adults With Elevated Lipoprotein(a)

A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

A Study of LY3079514 in Healthy Participants

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Continuous Transversus Abdominis Plane Nerve Block for Postoperative Analgesia

Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD

FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease

Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

Postoperative Pain Control After Periarticular Injection During Total Knee Arthroplasty

Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Hidradenitis Suppurativa Study of Izokibep

Liraglutide In Overweight Patients With Type 1 Diabetes

Study to Evaluate Safety of C-1101 Versus Sterile Saline in Adults With Chronic Painful Lumbosacral Radiculopathy

A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection

The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension